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Ebola virus exhibits a broad cellular tropism in vitro. In humans and animal models, virus is found in most tissues and
organs during the latter stages of infection. In contrast, a more restricted cell and tissue tropism is exhibited early in infection
where macrophages, liver, lymph node, and spleen are major initial targets. This indicates that cellular factors other than the
broadly expressed virus receptor(s) modulate Ebola virus tropism. Here we demonstrate that the C-type lectins DC-SIGN and
DC-SIGNR avidly bind Ebola glycoproteins and greatly enhance transduction of primary cells by Ebola virus pseudotypes and
infection by replication-competent Ebola virus. DC-SIGN and DC-SIGNR are expressed in several early targets for Ebola virus
infection, including dendritic cells, alveolar macrophages, and sinusoidal endothelial cells in the liver and lymph node. While
DC-SIGN and DC-SIGNR do not directly mediate Ebola virus entry, their pattern of expression in vivo and their ability totransmission, tissue tropism, and pathogenesis. © 2002 Els
INTRODUCTION
Ebola (EBO) virus has caused several major outbreaks
of severe hemorrhagic fever in Central Africa over the
last 25 years with documented fatality rates approaching
90% for subspecies Zaire (Who, International Study
Team, 1978). EBO and Marburg virus constitute the only
two members of the Filovirus family of negative-stranded
RNA viruses. EBO encodes a single heavily glycosylated
(over 50% of total mass) viral surface protein, GP. GP is a
major determinant of cellular and tissue tropism, pre-
sumably by mediating receptor binding and virus entry.
Recently, folate receptor- has been implicated in play-
ing a role in EBO entry into some, but not all, cell types
(Chan et al., 2001). Folate receptor- and other receptors
for EBO appear to be widely expressed as many cell
lines from multiple avian and mammalian species are
susceptible to infection by pseudotype viruses bearing
EBO-GP (Wool-Lewis and Bates, 1998). In addition, EBO
can be detected in virtually all organs and many cell
types, including tissue macrophages, endothelial cells,
hepatocytes, and fibroblasts in the terminal stages of
1 To whom correspondence and reprint requests should be ad-
dressed at Department of Microbiology, University of Pennsylvania, 225ence (USA)
disease (Baskerville et al., 1985; Fisher-Hoch and Mc-
Cormick, 1999; Ryabchikova et al., 1999a,b). In experi-
mental primate studies, however, cells of the monocyte/
macrophage lineage constitute a predominant early cell
target for infection and are thought to be responsible for
disseminating the virus to multiple target organs (Ryab-
chikova et al., 1999a,b; Schnittler and Feldmann, 1999).
Detection of EBO replication in organs also appears to
follow a distinct order, with liver, spleen, and lymph
nodes being early targets. Thus, specific receptors or
attachment factors may promote infection of certain cell
types. Identification of such factors will aid in the under-
standing and potential prevention of EBO transmission
and pathogenesis.
The C-type lectin DC-SIGN is expressed on a variable
proportion of alveolar macrophages, placental macro-
phages, and some types of dendritic cells, while its
closely related homolog DC-SIGNR is expressed on en-
dothelial cells in the liver and lymph node sinuses
(Bashirova et al., 2001; Geijtenbeek et al., 2000; Jameson
et al., 2002; Po¨hlmann et al., 2001c; Soilleux et al., 2000,
2002). Both proteins efficiently bind and transmit human
immunodeficiency virus (HIV) to receptor positive cells in
a carbohydrate-dependent manner and may promote HIV
dissemination in and between hosts (Bashirova et al.,efficiently capture virus and to enhance infection indicate t
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tains hybrid and high mannose carbohydrates (Geyer et
al., 1992) and it has recently been demonstrated that
DC-SIGN/DC-SIGNR selectively interact with high man-
nose sugars (Feinberg et al., 2001). Thus, the ability of
these lectins to interact with EBO-GPs and to influence
virus infection was investigated.
RESULTS
DC-SIGN and DC-SIGNR enhance binding and
transduction of EBO-GP pseudotypes
EBO-GP from the highly pathogenic Zaire subspecies
(EBOZ-GP) as well as the envelope proteins (Env) of
amphotropic murine leukemia virus (MLV) and vesicular
stomatitis virus (VSV) were pseudotyped onto HIV virus
cores. Binding of virus pseudotypes to DC-SIGN or DC-
SIGNR expressing 293T cells was analyzed at 4°C, since
under these conditions virus transduction of target cells
is negligible (Fig. 1A and data not shown). The presence
of DC-SIGN or DC-SIGNR had little or no effect on bind-
ing of virions bearing the VSV or MLV Env glycoproteins
(Fig. 1A). In contrast, EBOZ-GP pseudotype binding to
DC-SIGN/DC-SIGNR-expressing cells was strongly en-
hanced compared to control cells. EBOZ-GP pseudo-
types bound poorly to cells transfected with empty vec-
tor, despite the fact that such pseudotypes transduce
293T cells (Wool-Lewis and Bates, 1998). EBOZ-GP bind-
ing to DC-SIGN/DC-SIGNR was not limited to HIV-based
pseudotypes as MLV core particles pseudotyped with
EBOZ-GP also bound to DC-SIGN- and DC-SIGNR-ex-
pressing cells but only poorly to 293T cells expressing
vector alone (data not shown).
To determine whether enhanced binding of EBO-GP
pseudotypes to cells expressing DC-SIGN or DC-SIGNR
led to enhanced transduction, we challenged transiently
transfected 293T cells with HIV luciferase reporter vi-
ruses bearing EBOZ-GP, the GP from the less pathogenic
EBO Reston (EBOR-GP) subspecies, or the VSV-G protein
(Fig. 1B). 293T cells are susceptible to EBO pseudotype
transduction (Wool-Lewis and Bates, 1998), yet entry of
both types of EBO-GP pseudotypes into 293T cells was
enhanced over 8-fold by DC-SIGN and 14-fold by DC-
SIGNR expression (Fig. 1B). In contrast, DC-SIGN or
DC-SIGNR expression did not enhance transduction of
VSV-G-pseudotyped particles (Fig. 1B). Enhanced trans-
duction of EBOZ-GP particles due to DC-SIGNR expres-
sion was blocked by DC-SIGNR-specific monoclonal an-
tibody 604, while enhanced transduction due to DC-SIGN
expression was blocked by monoclonal antibody 526
that recognizes both DC-SIGN and DC-SIGNR (Fig. 1C)
(Baribaud et al., 2002). Enhanced transduction was also
prevented by mannan, a carbohydrate that blocks inter-
actions between DC-SIGN and its ligands (Geijtenbeek
et al., 2000), indicating that carbohydrate recognition was
important for EBO-GP interactions with DC-SIGN/DC-
SIGNR (Fig. 1C). These results are in agreement with a
recent study by Alvarez et al., who also found that ex-
pression of DC-SIGN or DC-SIGNR on cell lines en-
hanced virus pseudotype binding and transduction (Al-
varez et al., 2002).
To prove that enhancement of EBO-GP pseudotype
transduction was not limited to conditions of high DC-SIGN
surface expression, quantitative fluorescence-activated cell
sorting (Q-FACS) analysis was used to determine the cell-
surface copy numbers of DC-SIGN. Q-FACS relies on a
series of precalibrated beads that bind fixed numbers of
IgG molecules, allowing calculation of the absolute number
of antibody-binding sites on a cell (Lee et al., 1999). As few
as 40,000 copies of cell surface expressed DC-SIGN or
DC-SIGNR molecules were sufficient to significantly en-
hance EBOZ-GP-mediated transduction using an inducible
expression system to vary levels of DC-SIGN or DC-SIGNR
(Fig. 1D). Importantly, immature dendritic cells typically ex-
press more than 250,000 copies of DC-SIGN (Fig. 1E),
indicating that the effects we observed due to DC-SIGN/
DC-SIGNR expression in vitro occurred at surface expres-
sion levels that are physiologically relevant. To address the
specificity of interactions between DC-SIGN and Ebola vi-
rus pseudotypes, we also examined the ability of replica-
tion-competent herpes simplex virus type 1 (HSV-1) to en-
gage DC-SIGN (Fig. 1F), as this virus harbors several gly-
cosylated Env proteins, as well as HIV pseudotypes
bearing the glycoproteins from Lassa fever virus, MLV, or
VSV (Fig. 1G). Lassa fever virus and MLV-GP are both
heavily glycosylated, with Lassa-GP of the Josiah strain
containing 11 potential N-linked glycosylation sites (Au-
perin and McCormick, 1989) and MLV-GPs harboring up to
seven N- and seven O-linked glycosylation sites (Linder et
al., 1994). In contrast, VSV-G contains only two utilized
glycosylation sites (Hunt and Summers, 1977). We found
that HSV-1 infected target cells expressing high and low
levels of DC-SIGN/DC-SIGNR or the C-type lectin CD23
with similar efficiency and that the presence of DC-SIGN
did not enhance transduction of Lassa or VSV-G virus
pseudotypes (Fig. 1G). Infection by virus pseudotypes bear-
ing the MLV Env protein was enhanced slightly by high
levels of DC-SIGN expression (average of 295 cps at high
DC-SIGN levels compared to 65 cps at low levels). In
contrast, expression of DC-SIGN/DC-SIGNR but not CD23
strongly enhanced transduction by EBOZ-GP-bearing
pseudotypes (Fig. 1G). Thus, the mere presence of multiple
carbohydrates in a viral Env protein is not sufficient for
functional DC-SIGN/DC-SIGNR engagement, and enhance-
ment of EBOZ-GP-mediated infection was not observed
with a heterologous C-type lectin, indicating that the DC-
SIGN/DC-SIGNR interaction with EBO-GP is specific.
DC-SIGN and DC-SIGNR do not directly mediate EBO-
GP pseudotype transduction
The ability of DC-SIGN and DC-SIGNR to enhance
EBO-GP-mediated transduction prompted us to investi-
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FIG. 1. Enhancement of EBOZ-GP pseudotype binding and transduction by DC-SIGN and DC-SIGNR. (A) Binding of HIV pseudotypes bearing EBOZ-GP, VSV-G,
orMLVEnv toDC-SIGN,DC-SIGNR, or a control plasmid expressing 293T cells. The data are presented as%of recovered p24-antigen and represent the average
standard error of the mean (SEM) of three independent experiments. (B) DC-SIGN/DC-SIGNR-mediated enhancement of transduction with EBO-GP-bearing HIV
particles. Transduction of 293T cells transiently expressing DC-SIGN, DC-SIGNR, or a control plasmid with HIV-luciferase reporter viruses pseudotyped with the
EBOZ-GP, EBOR-GP, or VSV-G envelopes. The average  standard deviation (SD) of a single experiment carried out in triplicate is shown. Similar results were
obtained in two additional independent experiments. (C) Inhibition of EBOZ-GPbearingHIV pseudotype transduction byDC-SIGN- or DC-SIGNR-specific antibodies.
DC-SIGN/DC-SIGNR T-REx cells were induced with doxycycline and preincubated with 20 g/ml of the indicated antibodies or mannan. MAb 604 is specific for
DC-SIGNR, while MAb 526 recognizes both DC-SIGN and DC-SIGNR. mIgG indicates control murine IgG. Results are expressed as a percentage of virus
transduction in the absence of inhibitors, which resulted in approximately 15,000 and 45,000 counts per second (cps) for DC-SIGN andDC-SIGNR, respectively. The
results of a single experiment  SD carried out in triplicate are shown; comparable results were obtained in an independent experiment. (D) Assessment of
DC-SIGN copy numbers required for enhancement of EBOZ-GP-mediated transduction. T-REx DC-SIGN cells were seeded in duplicate, induced with doxycycline,
andDC-SIGNexpression and transduction efficiency analyzed in parallel. DC-SIGNexpressionwas assessed byQ-FACS,with the number of antibody-binding sites
obtained after each induction is indicated (left panel). The induced cells were transduced as described above and luciferase activity determined 3 days after
transduction (right panel). The results of a single experiment  SD are shown. The results were confirmed in an independent experiment. (E) Quantification of
DC-SIGN copy numbers on monocyte-derived dendritic cells as determined by Q-FACS. The value obtained exceeded the linear range of the assay, indicating that
these cells express at least 250,000 copies of DC-SIGN. Similar results were obtained in independent experiments with MDDC from different donors (Baribaud et
al., 2002). (F and G) Infection of DC-SIGN-, DC-SIGNR-, and CD23-expressing T-REx cells with herpes simplex virus 1 (HSV-1) or transduction by HIV pseudotypes
bearing theEBOZ, Lassa fever virus,MLV, or VSVglycoproteins. T-REx cells expressing the indicated lectinswere infectedwith a herpes virus simplex type-1 reporter
virus (F) or with the indicated pseudotypes (G). Infection of fully induced cells was compared to infection of uninduced cells, expressing relatively low levels of the
indicated lectins as determined by FACS (data not shown). The results of a single experiment  SD are shown. The results were confirmed in an independent
experiment.
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gate if these lectins function as cellular receptors for
EBO. Lentiviral vectors encoding DC-SIGN, DC-SIGNR,
or murine CD8 used as a negative control led to high
levels of expression upon transduction into primary
CD4 T cells which are not targets for EBO transduction
(Fig. 2A). Expression of DC-SIGN or DC-SIGNR did not
result in T cell transduction with EBOZ-GP pseudotypes
(Fig. 2B), although control 293T cells were efficiently
transduced. Moreover, VSV-G pseudotypes transduced
the T cells efficiently, confirming that the block to trans-
duction was at the level of virus entry (data not shown).
In addition, stable expression of DC-SIGN in the
promonocytic cell-line THP, which cannot be efficiently
transduced by EBOZ-GP pseudotypes, did not increase
susceptibility to transduction (data not shown). In con-
trast MLV pseudotypes transduced these cells efficiently
(data not shown). Thus, these proteins function as highly
efficient attachment factors for EBO, but do not function
as primary entry receptors in the cell types examined.
DC-SIGN and DC-SIGNR significantly enhance
transduction of primary cell types
In primates and humans, the liver is a primary target
organ of EBO infection (Ryabchikova et al., 1999a). DC-
SIGNR is expressed on liver sinusoidal endothelial cells
(Bashirova et al., 2001; Po¨hlmann et al., 2001c) where it
may help target virus to this organ. Indeed, in both
human postmortem material and animal models exten-
sive virus replication is seen in liver sinusoidal endothe-
lial cells, as judged by inclusion bodies formed by viral
core protein accumulation (Zaki et al., 1999). To explore
this possibility, we used lentivirus vectors to transduce
DC-SIGNR, DC-SIGN, or CCR5 as a control into primary
human umbilical vein endothelial cells (HUVECs). Ex-
pression of DC-SIGN or DC-SIGNR enhanced the trans-
duction of HUVECs with EBOZ-GP HIV pseudotypes (Fig.
3A). In contrast, DC-SIGN/DC-SIGNR expression did not
enhance VSV-G-mediated entry. When GFP-expressing
virus pseudotypes were used, FACS confirmed that the
DC-SIGNR-expressing endothelial cells were preferen-
tially transduced (Fig. 3B). Blocking experiments with
MAb 526, which binds to both DC-SIGN and DC-SIGNR,
FIG. 2. EBOZ-GP-mediated transduction of DC-SIGN/DC-SIGNR-ex-
pressing primary T cells. (A) Purified CD4 T cells were prepared from
whole blood, transduced with lentiviruses encoding DC-SIGN, DC-
SIGNR, or murine CD8, and expression verified by FACS. (B) The
transduced T cells as well as control 293T cells were transduced with
EBOZ-GP bearing HIV-GFP pseudotypes and the percentage of GFP-
positive CD4-expressing T cells or 293T control cells analyzed by
FACS. The results of a single experiment carried out in triplicate  SD
are shown. The results were confirmed in an independent experiment.
FIG. 3. EBOZ-GP-mediated transduction of DC-SIGN/DC-SIGNR expressing endothelial cells. (A) HUVECs transduced with DC-SIGN, DC-SIGNR,
or CCR5 encoding lentiviruses were transduced with EBOZ-GP or VSV-G bearing HIV pseudotypes. One representative experiment of three is shown.
Error bars indicate SD. (B) EBOZ-GP-bearing pseudotypes preferentially transduce DC-SIGN/DC-SIGNR-expressing cells. HUVECs were transduced
with a lentiviral vector encoding DC-SIGNR and challenged with EBOZ-GP bearing HIV GFP reporter virus. The amount of DC-SIGNR/GFP-expressing
cells was analyzed by FACS. (C) Inhibition of lentivirus-transduced HUVEC infection by DC-SIGN/DC-SIGNR-specific antibodies. Results are
expressed as a percentage of virus transduction in the absence of inhibitors. A representative experiment performed in triplicate is shown; similar
results were obtained in an independent experiment.
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confirmed that EBO-GP engagement of DC-SIGN/DC-
SIGNR was responsible for the enhanced entry into
HUVECs (Fig. 3C).
Cells of the monocyte/macrophage lineage represent
the predominant cell type infected early in infection and
are believed to be critical for the dissemination of virus to
target organs (Ryabchikova et al., 1999a,b; Schnittler and
Feldmann, 1999). DC-SIGN is expressed on a variable
fraction of human alveolar macrophages as well as on
placental macrophages. High levels of DC-SIGN expres-
sion on blood monocyte-derived macrophages (MDM)
can be induced by inflammatory cytokines such as IL-13
in vitro (Soilleux et al., 2002), indicating that other mac-
rophage types may express DC-SIGN during immune
stimulation in vivo. Indeed, systemic levels of inflamma-
tory cytokines are elevated during EBO infection
(Hutchinson et al., 2001; Leroy et al., 2001). We investi-
gated if DC-SIGN expression on MDM enhanced inter-
actions with EBO-GP. MDM were transduced with a
DC-SIGN encoding adenovirus (Ad/DC-SIGN) and incu-
bated with EBOZ-GP pseudotyped HIV particles, and the
amount of bound virus quantified (Fig. 4A). Virus particles
bound to DC-SIGN expressing MDM far more efficiently
than to control cells and binding was inhibited by prein-
cubation of MDM with MAb526 (Fig. 4A). DC-SIGN-trans-
duced MDM were about 5 to 12 times more susceptible
to EBO-GP pseudotypes than control macrophages (Fig.
4B). Q-FACS demonstrated that the transduced MDM
expressed similar levels of DC-SIGN as both cytokine-
induced macrophages and dendritic cells (data not
shown), indicating that the expression levels which pro-
moted EBO-GP pseudotype infection were similar to DC-
SIGN levels on primary cells. To determine whether
these results reflect infection with replication-competent
Ebola virus, a similar experiment was performed with live
Ebola virus Zaire (Figs. 4C–4F). MDM were transduced
with lentiviral vectors and Ebola virus infection was de-
tected by immunostaining for Ebola proteins. Despite a
transduction efficiency of only about 15% as judged by
FACS using MAb 526, the expression of either DC-SIGN
(Fig. 4E) or DC-SIGNR (Fig. 4F) rendered the MDMs
sixfold more susceptible to Ebola viral infection than
mock-transduced cells or cells transduced with control
vector (Figs. 4C and 4D).
DISCUSSION
The filoviruses exhibit a very broad cell tropism in
culture, animal models, and infected humans. The widely
expressed folate receptor- has been reported to medi-
ate entry of both Ebola and Marburg viruses in some cell
types (Chan et al., 2001). Nonetheless, tropism in various
animal models is much more limited early after infection.
Consequently, cellular factors other than the primary
receptor must contribute to EBO tropism and pathogen-
esis. Our results indicate that attachment factors such as
DC-SIGN and DC-SIGNR might be responsible for the
characteristic pattern of cell types and organs that are
predominantly infected during discrete stages of the dis-
ease by efficiently capturing virus and enhancing virus
infection. DC-SIGN is expressed on dendritic cells (DCs),
which often encounter invading pathogens at mucosal
surfaces. It has been proposed that HIV adsorbed to the
surface of DCs via DC-SIGN interactions may be trans-
ported to secondary lymphoid organs and ultimately
transmitted to receptor-positive cells (Geijtenbeek et al.,
2000). Our finding that EBO attaches to DC-SIGN sug-
gests that if the virus encounters DCs in vivo, which is
likely, it will bind to these cells efficiently and either infect
them or be transmitted to other susceptible cell types.
Indeed, a recent study by Alvarez et al. has shown that
virus pseudotypes bearing the EBO-GP can bind to DC-
SIGN on monocyte-derived dendritic cells and can be
transmitted to other cells once bound (Alvarez et al.,
2002). They also found that the expression of DC-SIGN or
DC-SIGNR on cell lines markedly enhanced infection by
virus pseudotypes. DC-SIGN is also expressed on alve-
olar macrophages that are early targets for infection
following aerosol transmission (Johnson et al., 1995), and
the DC-SIGN homolog DC-SIGNR is expressed on sinu-
soidal endothelial cells in the liver, an organ that is an
important early target for filovirus infection.
Binding of EBO to DC-SIGN and DC-SIGNR was inhib-
ited by addition of excess amounts of the carbohydrate
mannan, indicating that attachment of EBO to these lec-
tins is due to interactions between their carbohydrate
recognition domains and one or more N-linked carbohy-
drate structures on the EBO-GP. The recently solved
structure of these lectin domains coupled with carbohy-
drate-binding studies indicate that both DC-SIGN and
DC-SIGNR preferentially bind to high mannose carbohy-
drates, which may in part account for the specificity
exhibited by these lectins (Feinberg et al., 2001; Mitchell
et al., 2001). EBO-GP, similar to HIV-1 Env, is heavily
glycosylated with a variable number of its N-linked car-
bohydrate structures being fully processed upon trans-
port through the Golgi. The presence of immature, high-
mannose carbohydrate structures may be required for
efficient binding to DC-SIGN. However, since most lec-
tins bind to their ligands with relatively low affinity, the
presence of several high mannose chains that could
interact with several subunits in the DC-SIGN tetramer
might be needed for efficient binding (Mitchell et al.,
2001). If so, this could explain the efficiency with which
both HIV Env and EBO-GP bind to DC-SIGN and why
other viruses that bear one or more glycoproteins do not.
Most of our experiments, as well as all of the experi-
ments by Alvarez et al. (Alvarez et al., 2002), used retro-
virus pseudotypes bearing EBO-GPs. While useful exper-
imental models, retrovirus pseudotypes differ from repli-
cation-competent filoviruses, which are long and
filamentous. Thus, it was important that we confirmed
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that DC-SIGN expression on macrophages enhanced
infection by wild-type Ebola virus. Whether the effects of
DC-SIGN on infection by wild-type virus is less than,
similar to, or greater than the effects observed with viral
pseudotypes will require additional experiments. In ad-
dition, Ebola virus infected cells secrete a soluble ver-
sion of the viral glycoprotein. We have found that this
soluble protein also binds to DC-SIGN and DC-SIGNR
FIG. 4. EBOZ-GP-mediated binding and transduction of DC-SIGN-expressing macrophages. (A) Binding of EBOZ-GP-bearing HIV pseudotypes to
Ad/DC-SIGN or Ad/GFP transduced monocyte-derived macrophages. Macrophages were preincubated with DC-SIGN/DC-SIGNR-specific antibodies
or mannan. Binding is shown relative to levels of p24 observed with untreated, Ad/DC-SIGN-infected macrophages. Similar results were obtained in
an independent experiment. (B) Macrophages were transduced with lentiviruses expressing DC-SIGN or CCR5 as described above and 48 h later
transduced with HIV particles bearing EBOZ-GP. The cells were lysed 3 days later and luciferase activity was determined. The results represent the
average  SEM of four independent experiments. (C–F) Infection of macrophages with replication-competent EBO virus. Monocyte-derived
macrophages were transduced with the indicated lentiviruses and infected with the Zaire strain of Ebola virus using an m.o.i. of 0.1. Infected cells were
detected by immunostaining and the number of positive cells quantified. Representative fields are shown in (C–F). Of the mock-transduced cells about
2% stained positive for EBO (C), while approximately 1% of the CD8-transduced cells were virus positive (D). In contrast, virus infection was detected
in about 7% of the DC-SIGN (E) and about 8% of the DC-SIGNR-transduced cells (F). Similar levels of enhancement were obtained upon infection with
various m.o.i.s.
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(data not shown). Whether the presence of soluble gly-
coprotein will affect virus interactions with DC-SIGN and
DC-SIGNR in vivo is not known, though the presence of
multiple glycoproteins on virus particles will likely result
in an avid interaction with the surface of cells expressing
high levels of DC-SIGN.
Once bound to DC-SIGN, infection of either cell lines
or primary cell types by EBO pseudotypes or Ebola virus
was markedly enhanced. The mechanism for this en-
hancement is not entirely clear at present. However,
virus infection can be diffusion limited and the presence
of an efficient, high-affinity virus attachment factor may
enhance virus infection by capturing virus at the cell
surface where interactions with the receptors needed for
infection occur (O’Doherty et al., 2000; Po¨hlmann et al.,
2001d). DC-SIGN might also enhance EBO infection by
modifying GP conformation in a manner that enhances
its membrane fusion activity. In addition, DC-SIGN con-
tains endocytosis motifs in its cytoplasmic domain, and
once bound to DC-SIGN EBO, may be efficiently endo-
cytosed to acidic compartments where membrane fusion
is thought to take place (Wool-Lewis and Bates, 1998).
Additional work will be needed to fully characterize the
mechanism by which EBO binds to DC-SIGN and to
characterize how binding results in enhanced virus in-
fection.
The potential importance of C-type lectins in filovirus
infection is also underlined by the observation that Mar-
burg virus, which is closely related to EBO, uses the
C-type lectin asialoglycoprotein receptor (ASGP-R) for
efficient infection of hepatocytes (Becker et al., 1995).
The significance of DC-SIGN, DC-SIGNR, and the folate
receptor for filovirus infection in vivo will have to await
the development of specific antibodies or antagonists
that efficiently prevent interactions with the viral GP.
However, the expression of DC-SIGN and DC-SIGNR in
vivo coupled with the known tissue tropism of the filovi-
ruses early after infection and our demonstration that
these proteins serve as efficient attachment factors for
EBO virus suggest that these proteins can play important
roles in the early stages of rapidly progressive filovirus
infections. More generally, our results suggest that other
pathogens may take advantage of cell-surface proteins
to mediate efficient attachment and, as a result, signifi-
cantly enhance infection efficiency and dissemination
within the host.
MATERIALS AND METHODS
Plasmids
cDNAs encoding the Zaire and Reston subtypes of
EBO-GP were subcloned into the pCB6 expression plas-
mid as described previously (Simmons et al., 2002). The
coding sequence of CD23 was amplified from tissue
cDNA and cloned into pcDNA4 (Invitrogen). To detect
surface expression, an AU-1 tag was added using PCR-
based mutagenesis. The Lassa virus (strain Josiah) gly-
coprotein was PCR amplified and cloned into pCMV
(Clontech). pHIT60 (MLV gag/pol), pHIT111 (lacZ), and
DC-SIGN/DC-SIGNR expression plasmids have been
previously described (Po¨hlmann et al., 2001a,c; Soneoka
et al., 1995).
HIV pseudotype production and binding assay
HIV pseudotypes were generated by cotransfection of
293T cells with the indicated Env-encoding plasmids
together with the pNL4-3-Luc-RE plasmid as de-
scribed (Connor et al., 1995). The viral supernatants were
p24-normalized and the binding assay performed as pre-
viously described (Po¨hlmann et al., 2001a,c), with the
exception that pseudotypes and cells were incubated at
4°C to prevent infection.
Quantification of DC-SIGN copy numbers
Endogenous expression of cell-surface DC-SIGN was
analyzed on monocyte-derived dendritic cells (MDDCs).
Immature MDDCs were generated by purifying mono-
cytes from PBMC by discontinuous Percoll gradient cen-
trifugation and plastic adhesion and by culturing the cells
in RPMI 1640 supplemented with GM-CSF (50 ng/ml) and
IL-4 (100 ng/ml) for 7 days. The immature MDDC had the
following phenotype: HLA-DRhigh, CD11chigh, CD14,
CD80, CD83, as judged by flow cytometry (data not
shown). DC-SIGN expression on these cells was as-
sessed using a quantitative FACS technique (Q-FACS) as
described (Lee et al., 1999; Po¨hlmann et al., 2001a). In
brief, commercially available microbeads (Sigma, St.
Louis, MO) harboring defined numbers of antibody-bind-
ing sites were included in the FACS analysis and pro-
cessed similar to regular samples. The binding capacity
of the microbeads was used as a standard to extrapolate
the antibody-binding sites on the cells analyzed.
Transduction of 293T and DC-SIGN/DC-SIGNR-
expressing T-REx cells
293T cells were transiently transfected with pcDNA3,
DC-SIGN, or DC-SIGNR plasmids and seeded into 24-
well or 96-well plates. Forty-eight hours posttransfection,
cells were challenged overnight with 200 l (for 24-well
plate) of medium containing 800 TCID50 (as determined
on 293T cells) of HIV-luciferase pseudotypes bearing
EBOZ-GP, EBOR-GP, or VSV-G envelopes (Figs. 1B and
1G). Alternatively, virus stocks normalized for p24 antigen
content by ELISA (Coulter Beckman) were used for in-
fection (Fig. 1C). Fresh medium was added 12 h there-
after and luciferase expression was quantified 48 or 72 h
after transduction using a commercially available kit
(Promega, Madison, WI). T-REx cells (Invitrogen) that
inducibly express DC-SIGN/DC-SIGNR have been de-
scribed previously (Po¨hlmann et al., 2001a,b). Cells with
inducible CD23 expression were similarly generated us-
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ing the T-REx system. Gene expression was induced
with doxycycline overnight and cells were transduced
with pseudotypes bearing the EBOZ, Lassa fever virus,
VSV, or MLV glycoproteins as described for the tran-
siently transfected 293T cells. Infection by HSV-1 was
assessed using KOS/tk12, a replication-competent
HSV-1 reporter virus which carries a -galactosidase
expression cassette in the thymidine kinase locus of the
viral genome (Warner et al., 1998). -Galactosidase en-
zyme activity was assessed 7 h after infection using a
commercially available kit (Tropix). To correlate DC-SIGN
copy numbers and enhancement of infection, T-REx DC-
SIGN cells were seeded in duplicate wells and induced
overnight with increasing concentrations of doxycycline
and one panel was used for Q-FACS analysis, whereas
the second panel was used for infectivity studies as
described above.
Transduction and infection of PBMCs, HUVECs, and
macrophages with HIV pseudotypes bearing EBO-GP
Recombinant lentivirus pseudotypes expressing DC-
SIGN, DC-SIGNR, or CCR5 were generated by cotrans-
fection of 293T cells with plasmids encoding VSV-G en-
velope (pMD.G), a packaging construct (pMDLg/pRRE), a
Rev expression construct (RSV-Rev), and a modified
transfer vector construct (pRRL.SIN-18), in which the
HIV-1 cPPT element was added as previously described
(Dull et al., 1998). Recombinant adenoviruses expressing
DC-SIGN and GFP (Ad/DC-SIGN), or GFP alone (Ad/
GFP), were generated from pAdTrack-CMV/DC-SIGN or
pAdTrack-CMV/5RCC adenovirus shuttle vectors and
pAdEasy-1 adenoviral backbone using homologous re-
combination in bacteria as previously described (He et
al., 1998). PBMC were Ficoll isolated from whole blood of
healthy donors, CD4 T cells were purified by negative
magnetic bead selection and PHA and IL-2 stimulated for
3 days, and seeded in 24-well dishes. Human umbilical
vein endothelial cells (Clonetics) were set-up in a 48-well
plate at 2  104 cells per well in EGM medium (Clonet-
ics). Monocytes were purified by elutriation of an aphere-
sis product from a healthy donor. Monocyte-derived mac-
rophages were differentiated in RPMI containing 10%
human serum for 6 days and seeded in 48-well dishes.
The next day cells were challenged overnight with 150 l
of the lentiviral vectors at a 1:2 dilution or adenovirus
vectors at an m.o.i. of 75. After addition of 400 l of
medium, the cells were incubated for 2 days and then
challenged overnight with 150 l of medium containing
400 TCID50 (as determined on 293T cells) of HIV-lucif-
erase pseudotypes bearing EBOZ-GP or VSV-G enve-
lopes, or 2000 TCID50 of EBO-Z HIV-GFP pseudotypes
(Figs. 2B and 3A). Alternatively, cells were infected with
p24-normalized virus stocks (Figs. 3C and 4B). Fresh
medium was added the following day and luciferase
expression quantified 48 h after transduction or percent-
age of GFP-positive cells determined by FACS analysis
72 h after transduction. Binding assays using Ad/DC-
SIGN-transduced macrophages were performed as for
293T cells.
Infection of macrophages with EBO virus
Day 5 monocyte-derived macrophages were seeded
overnight at 2  105 in eight-well chamber slides (Bec-
ton-Dickinson, NJ). Cells were transduced with lentiviral
vectors as described above and 2 days posttransduction
were challenged with an m.o.i. of 0.1 of live EBO Zaire,
Mayinga strain. After a further 2 days the cells were fixed
and immunostained using polyclonal guinea pig sera
raised against EBO followed by an anti-guinea pig–FITC
conjugate. Slides were then observed by fluorescence
microscopy and numbers of EBO antigen-positive cells
per well were quantified.
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